Author: Annie Perinelli

Collaboration Leverages the OPTF01 product to Drive Next-Generation CAR-T Development The Woodlands, Texas and Ehime, Japan, May 8, 2025/ Cision / – Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Optieum Biotechnologies (Optieum), a preclinical stage company dedicated to the discovery and development of innovative Chimeric Antigen Receptor (CAR) T

The Woodlands and Dallas, Texas, January 22, 2025/ Cision / – Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Secretome Therapeutics, a biotechnology company advancing therapies derived from neonatal cardiac progenitor cells (nCPCs), today announced a partnership for cGMP manufacturing of Secretome Therapeutic’s lead asset STM-01. Under this partnership, Cellipont

BARLEV, ISRAEL, AND THE WOODLANDS, TEXAS — JANUARY 12, 2025 — ADVA Biotechnology and Cellipont Bioservices are proud to announce their participation at Advanced Therapies Week 2025, taking place in Dallas, Texas, from January 20–23, 2025. Together, they will present a showcase study highlighting how their collaboration successfully transitioned a CAR-T process from a complex manual

The Woodlands, Texas and Muskego, Wisconsin, December 10, 2024/ Cision / – Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Xiogenix, an innovator in biopharmaceutical technology, are pleased to announce a strategic partnership. This collaboration enables Cellipont Bioservices to offer its clients access to the state-of-the-art Ares™ X20 fill and